Detection of Tnf-Α Using the Established Ab-Mps-Clia

Abstract

Tumor necrosis factor alpha (TNF-α) is a crucial cytokine produced by the immune system, playing a significant role in the body. Accurate and rapid detection of TNF-α levels can help monitor disease progression and enable timely intervention. From the nine anti-TNF-α antibodies initially screened by our team, two antibodies demonstrating exceptional performance in chemiluminescence immunoassay (CLIA) were identified through epitope competition and antibody pairing. The detection method based on this antibody pair exhibits higher sensitivity than internationally recognized Siemens commercialized kits, with a linear range of 9.2 to 1077 pg/mL and a detection limit of 0.25 pg/mL (6.8 times lower than commercial kits, with a broader linear range), simpler instrument operation, and excellent clinical diagnostic performance.

Note:
Funding Information: This work was supported by the National Natural Science Foundation of China (82204262, 31970166), Beijing Nova Program (Z211100002121020, 20220484216), and Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX24_4148).

Conflict of Interests: The authors state no conflict of interest.

Ethical Approval: The research involving serum samples from healthy individuals complied with all relevant national regulations and institutional policies, and is in accordance with the tenets of the Helsinki Declaration (as amended in 2013). It has been approved (AF/SC08/02.344). The study in question has been approved by the Ethics Committee of the Academy of Military Medical Sciences, Beijing Institute of Pharmacology and Toxicology.

Keywords: TNF-α, CLIA, antibody, diagnosis